Drugs that slow aging and extend healthy years
Official title: Drug Targeting, Testing, and Development
Funded at Translational Genomics Research Inst · NIH-11399388 · Data updated 2026-11-12
A research project aims to find and test medicines that could slow aging and help people stay healthier longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | September 30, 2004 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $1,366,719 |
| NIH project number | 5U19AG023122-18 |
| Project ID | NIH-11399388 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults, including those around middle age, who might participate in future human studies or be involved through related samples or early trials.
✕Less likely to help
The project may not directly benefit any individual patient in the short term but could influence future therapies.
What this research studies
This project combines computer-based and laboratory methods to identify promising drugs that may slow aging. One team searches public data and chemical information to pick candidates, while another tests these candidates in mice and explores early human and dog studies. The goal is to find “geroprotectors” that influence aging-related changes and improve healthspan. Researchers will use aging-rate indicators measured in tissues and fluids to evaluate potential effects. If successful, this work could guide future human trials of aging-stopping therapies.
Why it matters
Potential benefit: If successful, the research could lead to new drugs that delay aging-related health decline and extend healthy years.
How similar studies have gone: Prior work with aging-rate indicators and geroprotectors has shown promise in animals, with exploratory human data supporting potential effects.
Where this research is happening
-
Translational Genomics Research Inst
Phoenix, United States Active
Researchers
- Principal investigator: Miller, Richard a — Translational Genomics Research Inst
- Study coordinator: Miller, Richard a
Related research
Other NIH-funded projects on the same topics.
-
CLU's role in Alzheimer's disease pathogenesis
Researchers are studying how the CLU gene may drive brain changes in Alzheimer's disease and how targeting CLU could lead to safer treatments.
-
How glioblastoma changes across the tumor and over time during treatment
This work maps how glioblastoma tumors shift their cell types and interactions during and after treatment to find weaknesses that could help people with recurrent GBM.
-
Understanding how early changes in lungs lead to progressive fibrotic disease
This grant studies the cells and genes involved in starting and advancing pulmonary fibrosis to uncover why some people progress to severe disease.
-
Integrative Analysis Core for Longevity and Dementia Research
A broad, shared analysis resource aims to bring together multiple studies on aging, longevity, and Alzheimer’s disease to better understand how genetics and other factors influence healthy aging.
-
Understanding Why Some People Age Well Despite Alzheimer’s and Related Dementias
Researchers are building patient-derived cell models to study why some people resist or slow down dementia and how aging affects brain cells, with a focus on Alzheimer’s Disease and related disorders.
-
Extreme longevity and brain health in centenarians and families
This grant studies why some people live to 100 with strong thinking skills and how genes and biomarkers relate to Alzheimer’s disease and related dementias, aiming to help others stay cognitively healthy as they age.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.